Every Form 4 that Abeona Therapeutics Inc. (ABEO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ABEO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ABEO filings page.
ABEONA THERAPEUTICS INC. (ABEO) director Mark Alvino reported selling 15,000 shares of common stock on 2026-09-01 in an open-market or private transaction. The weighted average sale price was $5.8644 per share, with individual trades executed between $5.80 and $5.9250 per share. Following this sale, Alvino directly holds 62,065 shares of ABEO common stock.
Vazzano Joseph Walter reported reported sale transactions in this Form 4 filing.
Abeona Therapeutics Chief Financial Officer Joseph Walter Vazzano reported that 1,478 shares of common stock were withheld at $6.53 per share to satisfy tax withholding obligations upon vesting of restricted stock awards. After this tax-related withholding, he directly holds 492,079 shares.
Abeona Therapeutics Inc. Chief Financial Officer Joseph Walter Vazzano reported an open-market sale of 24,880 shares of common stock at a weighted average price of $6.9637 per share. According to the filing, this sale was made to cover tax obligations tied to the vesting of restricted stock awards.
After this transaction, he directly holds 493,557 shares of Abeona common stock. The price reflects multiple trades executed between $6.86 and $7.04 per share.
Abeona Therapeutics Inc. chief executive officer Vishwas Seshadri reported an open-market sale of 67,971 shares of common stock at a weighted average price of $6.9637 per share. According to the filing, the sale was made to cover tax obligations from vesting restricted stock awards, and he continued to hold 1,306,108 shares afterward.
Abeona Therapeutics SVP and Chief Legal Officer Brendan M. O'Malley sold 12,050 shares of common stock on July 9, 2026 at a weighted average price of $6.9637 per share.
The company notes this sale was made to cover tax obligations from vesting of restricted stock awards. After the sale, O'Malley directly holds 427,953 shares of Abeona Therapeutics common stock.
Abeona Therapeutics Inc. Chief Commercial Officer Madhav Vasanthavada reported an open-market sale of 12,606 shares of common stock at a weighted average price of $6.9637 per share. After this transaction, he directly holds 290,623 shares, indicating that only a small portion of his position was sold.
Abeona Therapeutics director Alland Leila reported an open-market sale of company stock. On this Form 4, Leila sold 11,000 shares of Abeona Therapeutics common stock in a non-derivative, open-market transaction at a weighted average price of $5.917 per share.
The sale occurred through multiple trades on a single day at prices ranging from $5.915 to $5.9334 per share. After these transactions, Leila directly holds 162,614 shares of Abeona Therapeutics common stock.
Abeona Therapeutics Chief Commercial Officer Madhav Vasanthavada reported a routine compensation-related share adjustment. On a Form 4 dated for a transaction on June 16, 2026, 222 shares of common stock at $5.67 per share were withheld to satisfy tax obligations upon vesting of restricted stock awards. Following this withholding, he holds 303,229 common shares directly.
ABEONA THERAPEUTICS INC. director Christine Berni Silverstein reported an open-market sale of 18,160 shares of common stock. The shares were sold at a weighted average price of $5.7101 per share. According to the footnotes, this sale was made to cover tax obligations arising from the vesting of restricted stock awards. After the transaction, she directly owned 119,562 shares of Abeona common stock.
Abeona Therapeutics SVP and Chief Legal Officer Brendan M. O’Malley reported small stock sales primarily to cover taxes on vested awards. He sold 4,826 shares of common stock at a weighted average price of $5.4295 on June 8, 2026 and 6,305 shares at $5.3042 on June 9, 2026, totaling 11,131 shares. A footnote states the sales were made to cover tax obligations from vesting of restricted stock awards. After these transactions, he directly owned 440,003 shares of Abeona common stock.
Abeona Therapeutics’ Chief Financial Officer Joseph Walter Vazzano reported selling a total of 49,338 shares of common stock in open-market transactions on June 8–9, 2026 at weighted average prices around $5.30–$5.43 per share. According to the disclosure, these sales were made to cover tax obligations arising from the vesting of restricted stock awards and were carried out under a Rule 10b5-1 trading plan adopted on January 21, 2026. Following the transactions, Vazzano directly holds 518,437 shares of Abeona Therapeutics common stock.
Abeona Therapeutics’ Chief Commercial Officer Madhav Vasanthavada reported small stock sales primarily for tax purposes. On June 8, he sold 4,170 shares of common stock in open-market transactions at a weighted average price of $5.4295 per share. On June 9, he sold another 5,450 shares at a weighted average price of $5.3042 per share. A footnote explains that these sales were made to cover tax obligations tied to the vesting of restricted stock awards, indicating they are compensation-related rather than discretionary portfolio trades. After these transactions, he directly held 303,451 shares of Abeona common stock.
Abeona Therapeutics CEO Vishwas Seshadri reported selling a total of 56,344 shares of common stock in open-market transactions on June 8 and 9, 2026. According to the disclosure, these sales were made to cover tax obligations associated with the vesting of restricted stock awards.
After these tax-related sales, Seshadri directly owns 1,374,079 shares of Abeona Therapeutics common stock.
Abeona Therapeutics director Mark Alvino reported a bona fide gift of 500 shares of Common Stock. The gift was recorded at a price of $0.00 per share, reflecting a non-market, no‑consideration transfer. Following this disposition, he directly holds 77,065 shares of Abeona Therapeutics common stock.
Abeona Therapeutics director Mark Alvino reported an open-market sale of company stock. He sold 6,500 shares of common stock on May 22, 2026 at a weighted average price of $5.4558 per share, through multiple trades priced between $5.44 and $5.47.
After this transaction, Alvino directly holds 77,565 shares of Abeona Therapeutics common stock. The filing notes that full details of the individual trade prices within the reported range are available upon request.
Abeona Therapeutics director Eric Crombez reported an open-market sale of 26,143 shares of common stock on May 15, 2026 at a weighted average price of $5.5325 per share. The sale was executed under a Rule 10b5-1 trading plan adopted on February 4, 2026, indicating the transactions were pre-arranged. Following this sale, Crombez directly holds 37,313 shares of Abeona Therapeutics common stock.
Abeona Therapeutics Inc. Chief Commercial Officer Madhav Vasanthavada reported an open-market sale of 5,548 shares of common stock at a weighted average price of $5.9613 per share. According to the filing, this sale was made specifically to cover tax obligations from the vesting of restricted stock awards, making it a mechanistic transaction rather than a discretionary portfolio change. Following the sale, Vasanthavada directly holds 313,071 shares of Abeona common stock, so the transaction represents a small portion of his overall reported holdings.
Goldan Keith A. reported acquisition or exercise transactions in this Form 4 filing.
Abeona Therapeutics Inc. director Keith A. Goldan received a grant of restricted common stock. He was awarded 32,751 shares of common stock at a stated price of $0.00 per share, increasing his directly held position to 32,751 shares after the transaction.
According to the filing, all of this restricted stock will vest on April 1, 2027, meaning the shares are subject to service-based conditions until that date and are compensation-related rather than an open-market purchase.
Abeona Therapeutics Inc. CEO Vishwas Seshadri sold 29,985 shares of common stock in an open-market transaction. The sale occurred on March 31, 2026 at a weighted average price of $4.3849 per share, with individual trades between $4.31 and $4.43.
After the transaction, Seshadri directly held 1,430,423 shares of Abeona common stock. The filing states that the sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on September 17, 2024, indicating it was scheduled in advance.
Abeona Therapeutics Inc.’s Chief Financial Officer Joseph Walter Vazzano reported an open-market sale of 785 shares of common stock. The shares were sold at $4.76 each on the transaction date to cover tax obligations associated with the vesting of restricted stock awards. After this transaction, he directly holds 567,775 shares of Abeona common stock.
Abeona Therapeutics director Christine Berni Silverstein reported a tax-related stock sale. On February 2, 2026, she sold 20,070 shares of common stock at a weighted average price of $5.0906 per share. After this transaction, she beneficially owned 137,722 shares, held directly.
The filing notes the sale was made to cover tax obligations arising from the vesting of restricted stock awards, indicating the transaction was tied to equity compensation rather than a discretionary open-market liquidation. The price range for the sales was between $5.09 and $5.12 per share.
Abeona Therapeutics director Donald A. Wuchterl reported a small stock sale mainly for tax purposes. On 02/02/2026, he sold 14,814 shares of Abeona Therapeutics common stock at a weighted average price of $5.0906 per share to cover tax obligations from vesting restricted stock awards.
After this transaction, he directly owned 167,935 shares of Abeona common stock. The shares were sold in multiple trades within a narrow price range from $5.09 to $5.12 per share.
Abeona Therapeutics director Eric Crombez reported a sale of company stock. On 02/02/2026, he sold 16,284 shares of Abeona Therapeutics common stock at a weighted average price of $5.0906 per share in market transactions.
According to the disclosure, this sale was made to cover tax obligations arising from the vesting of restricted stock awards. After these transactions, Crombez beneficially owned 63,456 shares of Abeona Therapeutics common stock directly.
Abeona Therapeutics director Leila Alland reported selling 18,065 shares of common stock on February 2, 2026 at a weighted average price of $5.0906 per share. The sale was made to cover tax obligations from the vesting of restricted stock awards, and she now beneficially owns 173,614 shares directly.
Abeona Therapeutics director Mark Alvino reported a small share sale to cover taxes. On February 2, 2026, he sold 2,000 shares of common stock in Abeona Therapeutics at a weighted average price of $5.0906 per share.
The filing explains that the sale was made to satisfy tax obligations arising from the vesting of restricted stock awards, rather than as a discretionary portfolio decision. After this transaction, Alvino directly beneficially owned 84,065 shares of Abeona Therapeutics common stock, and no derivative securities were reported.
Abeona Therapeutics director Donald A. Wuchterl reported receiving 37,313 shares of common stock as restricted stock on January 26, 2026, at a price of $0.00 per share. After this grant, he directly holds 182,749 shares of Abeona common stock.
According to the filing, all of this restricted stock will vest on January 26, 2027, meaning the shares become fully owned by him on that date if the vesting conditions are met.
Abeona Therapeutics Inc. director Bernhardt G. Zeiher received a grant of 37,313 shares of common stock on January 26, 2026. The shares were awarded at a price of $0.00 per share as restricted stock. After this grant, he directly holds 84,458 shares. All of the restricted stock will vest on January 26, 2027, meaning the award becomes fully owned on that date if conditions are met.
Abeona Therapeutics director Eric Crombez received a new equity grant. On January 26, 2026, he was awarded 37,313 shares of Abeona Therapeutics common stock as restricted stock at a price of $0.00 per share. After this grant, he directly owns 79,740 common shares.
The filing states that all of this restricted stock will vest on January 26, 2027, meaning the shares become fully earned on that date if vesting conditions are satisfied.
Abeona Therapeutics director receives restricted stock grant. Director Christine Silverstein Berni was awarded 37,313 shares of Abeona Therapeutics common stock on January 26, 2026 at a price of $0.00 per share. All of this restricted stock will vest on January 26, 2027.
Following this grant, she beneficially owns 157,792 shares of Abeona Therapeutics common stock in direct ownership.
Abeona Therapeutics director Michael Amoroso received a stock grant. On January 26, 2026, he was awarded 37,313 shares of Abeona Therapeutics common stock at a price of $0.00 per share as restricted stock. After this grant, he beneficially owned 217,779 shares directly. All of the restricted stock is scheduled to vest on January 26, 2027.
Abeona Therapeutics director Faith L. Charles received an equity grant of 37,313 shares of common stock as restricted stock on January 26, 2026. The award was reported at a price of $0.00 per share, reflecting a stock-based compensation grant rather than an open-market purchase.
Following this grant, Charles beneficially owns 176,407 shares of Abeona common stock in direct form. All of the restricted stock from this award is scheduled to vest on January 26, 2027, aligning her compensation with the company’s future performance over the vesting period.
Abeona Therapeutics director Mark Alvino received a grant of 37,313 shares of common stock on January 26, 2026, at a price of $0.00 per share. These are restricted shares that will fully vest on January 26, 2027. Following this award, he beneficially owns 86,065 shares directly.
Abeona Therapeutics Inc. director Leila Alland received a grant of 37,313 shares of common stock on January 26, 2026 at a price of $0.00 per share. This reflects an equity-based award rather than a cash purchase.
All of the restricted stock is scheduled to vest on January 26, 2027. Following this grant, Alland beneficially owns 191,679 shares of Abeona common stock in direct ownership, according to the filing.
Abeona Therapeutics Chief Commercial Officer Vasanthavada Madhav reported a new stock grant and a related share sale. On January 20, 2026, he received 76,621 shares of restricted common stock at $0.00, which will vest in three equal parts on January 20, 2027, January 20, 2028, and January 20, 2029. On January 22, 2026, he sold 12,610 shares of common stock at a weighted average price of $5.2861 per share to cover tax obligations from restricted stock vesting. After these transactions, he directly beneficially owned 318,619 shares of Abeona common stock.
Abeona Therapeutics’ Chief Financial Officer Joseph Walter Vazzano sold 18,666 shares of common stock on January 22, 2026 at a weighted average price of $5.3309 per share. The filing explains that this sale was made to cover tax obligations tied to the vesting of restricted stock awards, meaning it was related to compensation rather than an open-market liquidation of a large personal position.
After this tax-related sale, Vazzano beneficially owned 568,560 shares of Abeona common stock directly. The reported price reflects multiple trades in a range from $5.33 to $5.38 per share, aggregated into a single weighted average figure in the filing.
Abeona Therapeutics CEO Vishwas Seshadri, who also serves as a director, reported a sale of company common stock. On January 22, 2026, he sold 69,832 shares of Abeona Therapeutics common stock in an open market transaction coded as a sale. The shares were sold at a weighted average price of $5.3309 per share, through multiple trades at prices ranging from $5.33 to $5.38.
According to the filing, this sale was made to cover tax obligations associated with the vesting of restricted stock awards. After the transaction, Seshadri beneficially owned 1,460,408 shares of Abeona Therapeutics common stock directly.
Abeona Therapeutics SVP and Chief Legal Officer Brendan M. O'Malley reported a sale of company stock. On January 22, 2026, he sold 13,578 shares of common stock at a weighted average price of $5.3309 per share. According to the filing, the sale was made to cover tax obligations associated with the vesting of restricted stock awards, meaning it was tied to equity compensation rather than an open-market discretionary sale of his full holdings. After this transaction, O'Malley beneficially owned 451,134 shares of Abeona common stock directly.
Abeona Therapeutics Inc. director Mark Alvino reported selling 13,500 shares of the company’s common stock on 01/21/2026. The shares were sold at a weighted average price of $5.2277 per share, with individual trade prices ranging from $5.21 to $5.235. After this transaction, he beneficially owns 48,752 common shares directly.
The filing notes that detailed price and size information for each individual trade within the reported price range is available upon request from the company, any security holder, or the SEC staff.
Abeona Therapeutics reported an insider equity award to its Chief Financial Officer, Joseph Walter Vazzano. On January 20, 2026, he received 133,595 shares of common stock as restricted stock at a price of $0.00 per share, indicating a stock-based compensation grant rather than an open-market purchase. According to the disclosure, these restricted shares will vest in three equal installments on January 20, 2027, January 20, 2028, and January 20, 2029. Following this grant, Vazzano directly beneficially owns 587,226 shares of Abeona Therapeutics common stock.
Abeona Therapeutics Inc. disclosed an equity grant to its Chief Executive Officer and director, Vishwas Seshadri. On January 20, 2026, he received 365,422 shares of common stock as restricted stock at a price of $0.00 per share. After this award, he beneficially owned 1,530,240 shares of Abeona common stock in total.
The restricted stock will vest in three equal installments, with one-third of the shares scheduled to vest on each of January 20, 2027, January 20, 2028, and January 20, 2029, aligning the CEO’s compensation with the company’s multi‑year performance.
Abeona Therapeutics reported an insider equity award for its SVP and Chief Legal Officer, Brendan M. O'Malley. On January 20, 2026, he received 113,949 shares of common stock as restricted stock at a price of $0.00 per share, reflecting a compensatory grant rather than an open-market purchase.
The restricted stock will vest in three equal installments, with one-third vesting on January 20, 2027, one-third on January 20, 2028, and the final third on January 20, 2029. Following this award, O'Malley beneficially owns 464,712 shares of Abeona Therapeutics common stock, held directly.
Abeona Therapeutics (ABEO) CEO and Director Vishwas Seshadri reported a Form 4 transaction. He sold 249 shares of common stock on 10/16/2025 at $5.485 per share, a sale described as to cover tax obligations from the vesting of restricted stock awards.
Following the transaction, he beneficially owns 1,189,818 shares, held directly.
ABEO Form 4 summary: Brendan M. O'Malley, Senior Vice President and Chief Legal Officer of Abeona Therapeutics (ABEO), reported a sale of 9,366 shares of common stock on 09/29/2025 at a weighted average price of $5.3935 per share. After the sale, he beneficially owns 350,763 shares. The filing states the sale was executed to cover tax obligations arising from the vesting of restricted stock awards and that the reported price reflects multiple transactions ranging from $5.35 to $5.46.
Insider sales reported by Vishwas Seshadri, CEO and Director of Abeona Therapeutics (ABEO). The Form 4 shows two non-derivative sales: 19,274 shares sold on 09/29/2025 at a weighted average price of $5.3935 to cover tax obligations from restricted stock vesting, and 25,000 shares sold on 09/30/2025 at a weighted average price of $5.2372 under an existing Rule 10b5-1 trading plan. The reporting persons beneficial ownership decreased from 1,215,067 shares to 1,190,067 shares following these transactions. The filing is signed by Vishwas Seshadri on 10/01/2025.
Joseph Walter Vazzano, Chief Financial Officer of ABEONA THERAPEUTICS INC. (ABEO), reported the sale of 9,035 shares of common stock on 09/29/2025. The disclosed weighted-average price was $5.3935 per share, with individual trade prices ranging between $5.35 and $5.46. The filing states the shares were sold to cover tax obligations arising from the vesting of restricted stock awards. After the reported sale, the reporting person beneficially owned 453,631 shares, held directly. The Form 4 reflects a routine tax-related disposition rather than a market-timing or strategic sale.
Brendan M. O'Malley, Senior Vice President and Chief Legal Officer of Abeona Therapeutics, reported a single non-derivative transaction on 09/22/2025. The Form 4 shows a sale of 688 shares of Abeona common stock at $5.43 per share, executed to cover tax obligations tied to the vesting of restricted stock awards. After the sale, Mr. O'Malley is reported to beneficially own 360,129 shares directly. The filing is submitted by one reporting person and is signed by Mr. O'Malley on 09/22/2025. The disclosure is limited to this transaction and its stated tax-related purpose.